Afatinib Plus Toripalimab in Previously Treated ESCC With EGFR Overexpression or EGFR Amplification
Status:
Not yet recruiting
Trial end date:
2023-05-01
Target enrollment:
Participant gender:
Summary
This is a phase 2 trial investigating the effect and safety of afatinib plus toripalimab in
previously treated recurrent or metastasic esophageal squamous cell carcinoma with EGFR
overexpression or EGFR amplification.